Use of SGLT2 inhibitors was also linked to a decreased risk of (i) all-cause and CV death, (ii) CV hospitalisation and HHF and (iii) CV death/myocardial infarction/stroke. This evidence concerns the gene SLC5A2 and stroke disorder.